Navigation Links
Genzyme Reports Strong Second-Quarter Growth
Date:7/23/2008

ymphocytic leukemia.

Genzyme took a number of major steps during the second quarter to create opportunities for growth beyond 2011 by significantly strengthening its pipeline and expanding its global infrastructure:

-- The company secured exclusive worldwide rights to mipomersen, an innovative cholesterol-lowering drug in Phase 3 development that has the potential to change the standard of care for severely ill patients whose needs cannot be addressed by current therapies.

-- Genzyme also formed a collaboration this month with PTC Therapeutics to develop and commercialize PTC124, a novel oral therapy under development initially for Duchenne muscular dystrophy and cystic fibrosis. The product has broad potential in a range of other inherited disorders.

-- Genzyme continued to enroll patients in two ongoing Phase 3 trials of alemtuzumab for the treatment of multiple sclerosis. Final, three-year efficacy and safety data from the Phase 2 trial comparing alemtuzumab with Rebif(R) (interferon beta-1a) for the treatment of relapsing-remitting multiple sclerosis were presented during the quarter as part of a scientific platform session at the American Academy of Neurology. The company is awaiting publication of these results.

-- Genzyme announced plans for a research and development center in China and also began building a commercial organization in India, initiatives that reflect the company's commitment to establishing a long-term presence in both countries.

This press release contains forward-looking statements regarding Genzyme's financial outlook and business plans and strategies, including without limitation: its 2008 earnings guidance; its expectations for approval of Myozyme produced at the 2000L and 4000L-scale capacities, the timing thereof and its assessment of product supply; its plans to seek regulatory approvals of existing products for use in new indications, including Renvela for CKD and Clolar for adult AML, the ti
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014  The Society for Clinical Research Sites ... for the 9 th annual Site Solutions ... Amelia Island , Florida.  The focus on collaboration ... however, the topics and format will allow for ... all stakeholders with a continued focus on site ...
(Date:7/29/2014)... 2014 According to the new ... Analytics (Image Analysis Software), Delivery Modes (Web Based/Cloud Based) ... Trends to 2018", published by MarketsandMarkets, analyzes and studies ... as North America , ... the Rest of the World (RoW). Browse ...
(Date:7/29/2014)... , July 29, 2014 A ... equipment market (types, applications and geography) - Size, Share, ... Opportunities, Segmentation and Forecast, 2013 - 2020", suggests that ... $12.1 billion by 2020 registering a CAGR of 11.1% ... breakthrough achieved by the electro surgical devices in operative ...
(Date:7/29/2014)... CO (PRWEB) July 29, 2014 TransVac ... soiled linen collection and transport solutions for hospitals, will ... for Healthcare Engineering (ASHE) Annual Conference & Technical Exhibition ... will present its technology for making hospitals cleaner, reducing ... costs over the hospital’s life cycle. Staff will ...
Breaking Biology Technology:TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 3Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 3TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2
...   BioLife Solutions Inc. (OTCBB: BLFS), a leading developer, ... cryopreservation freeze media for cells and tissues, today ... calendar year 2011. Highlights include: , Sixth consecutive quarter ... $809,000, up 13% over the third quarter and 41% over ...
...  Omeros Corporation (NASDAQ: OMER ) today reported that ... GPR25, GPR32, GPR80, GPR135 and MAS1, bringing the total number ... 23, representing 30 percent of the Class A orphan GPCRs. ... drug development equals half of the total number of GPCRs ...
... BEIJING, Jan. 10, 2012 The global fight against ... and the China National Biotec Group (CNBG) announce that ... tuberculosis (TB) vaccines. The agreement between the leading non-profit ... corporation in China signals a commitment by both to ...
Cached Biology Technology:BioLife Solutions 2011 Revenue Up 33% 2BioLife Solutions 2011 Revenue Up 33% 3Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs 2Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs 3Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs 4Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs 5Aeras and CNBG Sign Agreement on Tuberculosis Vaccine R&D 2Aeras and CNBG Sign Agreement on Tuberculosis Vaccine R&D 3
(Date:7/30/2014)... online today in the journal Scientific Reports , ... and Auroop Ganguly found that while global temperature is ... extremes. For instance, while each year,s average hottest and ... tend to fall within a wider range of potential ... observed. This means that even as overall temperatures rise, ...
(Date:7/29/2014)... wrong food at a restaurant, don,t blame yourself; blame the ... with what you want and more to do with a ... the selections of over 300 diners, the Cornell study published ... showed that when it comes to what you order ... the menu and how you imagine it will taste. , ...
(Date:7/29/2014)... remote UK overseas territory of Ascension Island, one of ... of a renaissance. , Writing in the journal ... Exeter and Ascension Island Government Conservation Department report that ... South Atlantic outpost has increased by more than 500 ... many as 24,000 nests are now estimated to be ...
Breaking Biology News(10 mins):Big data confirms climate extremes are here to stay 2Menu secrets that can make you slim by design 2Major turtle nesting beaches protected in 1 of the UK's far flung overseas territories 2
... team of researchers, led by Virginia Bioinformatics Institute Professor ... grant from the National Science Foundation (NSF) to develop ... of drought on a variety of staple food crops. ... change and rapid population growth, can limit crop production, ...
... new light on the microscopic antennas in the kidney that ... work may be a crucial step towards a cure for ... than one in 1000 people. The study, led ... Inflammatory Disease at the Monash Medical Centre, showed how kidney ...
... RANCH, Calif., Sept. 29 Fujitsu ... supplier of innovative computer products including peripherals and biometric ... in Butler, Mo. is using the Fujitsu PalmSecure(TM) palm ... PalmSecure will replace Bates County Memorial,s existing fingerprint-based biometric ...
Cached Biology News:National Science Foundation funds systems biology study of crop drought responses 2National Science Foundation funds systems biology study of crop drought responses 3Australian study sheds light on kidney repair and disease 2Bates County Memorial Hospital Integrates Fujitsu PalmSecure Biometric Solution Into New Time and Attendance System 2Bates County Memorial Hospital Integrates Fujitsu PalmSecure Biometric Solution Into New Time and Attendance System 3Bates County Memorial Hospital Integrates Fujitsu PalmSecure Biometric Solution Into New Time and Attendance System 4
... Orbital Shaker is designed to be a solid, ... motion that is both mixing and vortexing in ... provides a smooth, quiet, reproducible and uniform orbital ... of laboratory applications such as cell/tissue culture, hybridization, ...
... The Biometra TProfessional Thermocycler combines top ... silver block achieves high speed and unparalleled ... graphical display providing programming in a spreadsheet ... High Performance Smart Lid opens on the ...
... Isolation Kit provides all the reagents ... vesicle fraction. The isolation procedure involves ... synaptosomes, and differential centrifugation followed by ... also contains an antibody specific for ...
... DNA Kit enables efficient extraction of DNA fragments from ... agarose gels. The procedure uses GelMelt solution to dissolve ... to a silica membrane in a spin column format. ... in low-salt buffer. Each spin column can bind up ...
Biology Products: